Published individual cases and study cohorts, with administration, follow-up and limitations shown together.
SEE / UNDERSTAND / ASK
Understand the science visually
Open any image at full size. Research pictures, original schematics and generated concepts are labelled separately; none is an Aurelia patient outcome.
Principle schematic
Research evidence is not clinical permission
Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.
Human embryonic-stem-cell-derived neural progenitors after three weeks of maturation, with morphology and immune markers. Not iPSC or treatment-response images.
An individual case is not a trial average. Different diseases, cell products and endpoints cannot be compared as a universal success rate. We redraw published numbers, not patient portraits.
Historical published research, not Aurelia patients or a claim that these treatments are offered here. Individual results and trial means are labelled separately.
01 / Cell 2024 · phase I report · n=1
Type 1 diabetes CiPSC-derived islets
Administration: CiPSC-derived islets transplanted beneath the abdominal rectus sheath; not a routine intravenous infusion.
One patient’s time in target glucose range rose from 43.18% to 96.21% at month 4; the report describes insulin independence from day 75 and follow-up to one year.
Time in target range · higher is betterView exact data
Measurement
Value
Baseline
43.18%
Month 4
96.21%
Limits and risks
A single uncontrolled case. Previous liver transplantation and existing immunosuppression prevent concluding that autologous cells avoid immune rejection or need no immunosuppression. One year of observation does not establish long-term safety.
Administration: Bilateral intracerebral putamen transplantation; tacrolimus was used.
Mean MDS-UPDRS III OFF motor score was 50.8 at baseline and 41.3 at 24 months in the six-person efficacy group. These are published table means, not a percentage-based reconstruction.
MDS-UPDRS III OFF · lower is betterView exact data
Measurement
Value
Baseline
50.8 points · SD 14.6
Month 24
41.3 points · SD 18.5
Mean (SD), n=6. Full scale 0–132; Extended Data Table 2.
Limits and risks
Small, uncontrolled study. Other endpoints did not consistently improve; the table’s dyskinesia mean increased from 21.0 to 33.3. Absence of serious events in this cohort does not mean zero risk. These trial results are not postoperative data for the 2026 commercial-use patient.
03 / JAMA 2019 · randomised trial · 110 randomised, 98 assessed at one year
Multiple sclerosis autologous HSCT
Administration: Autologous haematopoietic transplantation after immunosuppressive conditioning; immune reconstitution, not direct nerve regeneration.
At one year, mean EDSS moved from 3.38 to 2.36 with HSCT and from 3.31 to 3.98 with continued disease-modifying therapy. Each arm randomised 55 people.
EDSS · lower is betterView exact data
Measurement
Value
HSCT · baseline
3.38 points
HSCT · year 1
2.36 points
DMT · baseline
3.31 points
DMT · year 1
3.98 points
Limits and risks
Selected highly active relapsing-remitting MS; not all MS. The regimen includes chemotherapy and immune reconstitution, not direct nerve regeneration. Median follow-up was two years; only 23 had annual five-year evaluation. Infection and conditioning risks remain.
Administration: Surgical placement of allogeneic iPSC-derived corneal epithelial sheets.
Patient 1’s corrected distance vision, logMAR, changed from 1.52 before transplantation to 0.52 at week 52. Decimal vision was 0.03 and 0.30 respectively; these are two expressions of the same endpoint.
Patient 1 · logMAR, lower is betterView exact data
Measurement
Value
Before transplant
1.52
Week 52
0.52
One patient, not the mean of all four. Axis 0–3 is the plotted range.
Limits and risks
Four participants, no control. This patient used low-dose ciclosporin and postoperative steroids. Small numbers and limited follow-up cannot establish long-term safety or universal visual recovery.
MSC intravenous therapy defined paediatric indication
Administration: Intravenous donor bone-marrow MSC product, given under a defined protocol.
At day 28, 16 of 54 participants had complete response and 22 had partial response. This is a response distribution, not a fabricated baseline-to-after measurement.
Day 28 · response counts, n=54View exact data
Measurement
Value
Complete
16 people
Partial
22 people
Other
16 people
Other = 54−16−22, calculated remainder; no baseline response percentage is claimed.
Limits and risks
US approval is for steroid-refractory acute graft-versus-host disease in patients aged at least two months, not general anti-ageing. Infusion reactions and infections are among the risks; this study had no concurrent control.